David Walt, PhD

Harvard Medical School/Brigham and Women's Hospital/Wyss Institute

Disclosure(s): Quanterix Corporation: Ownership Interest; Simoa technology: Board Member, Ownership Interest

Poster(s):

• (P-1422) Immunogenicity and Reactogenicity of Adjuvanted (Arexvy) and Non-Adjuvanted (Abrysvo) RSV Vaccines in Immunocompromised Individuals with Hematological Malignancies
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET